E. Jaeger

1.7k total citations
39 papers, 1.2k citations indexed

About

E. Jaeger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E. Jaeger has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in E. Jaeger's work include Immunotherapy and Immune Responses (10 papers), Gastric Cancer Management and Outcomes (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). E. Jaeger is often cited by papers focused on Immunotherapy and Immune Responses (10 papers), Gastric Cancer Management and Outcomes (9 papers) and Colorectal Cancer Treatments and Studies (7 papers). E. Jaeger collaborates with scholars based in Germany, United States and Switzerland. E. Jaeger's co-authors include Alexander Knuth, Salah‐Eddin Al‐Batran, Julia Karbach, Barbara Seliger, Manfred Hagedorn, Helga Bernhard, Mark Ringhoffer, Michael Arand, Pedro Romero and Stefan Störkel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

E. Jaeger

36 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Jaeger Germany	16	621	463	413	408	233	39	1.2k
John E. Mullinax United States	19	681 1.1×	408 0.9×	204 0.5×	221 0.5×	390 1.7×	71	1.2k
Yukishige Yamada Japan	19	1.2k 2.0×	652 1.4×	461 1.1×	857 2.1×	541 2.3×	46	2.3k
Yuji Ichiyoshi Japan	25	598 1.0×	758 1.6×	324 0.8×	627 1.5×	459 2.0×	57	1.8k
Jacob R. Izbicki Germany	18	576 0.9×	357 0.8×	92 0.2×	284 0.7×	394 1.7×	47	1.3k
Xueli Bai China	20	993 1.6×	448 1.0×	447 1.1×	352 0.9×	427 1.8×	70	1.5k
H Sawada Japan	15	503 0.8×	404 0.9×	99 0.2×	669 1.6×	239 1.0×	39	1.3k
Satoshi Nishiwada Japan	18	853 1.4×	330 0.7×	252 0.6×	252 0.6×	388 1.7×	56	1.2k
Deepti Aurora-Garg United States	18	1.1k 1.7×	701 1.5×	229 0.6×	173 0.4×	202 0.9×	28	1.3k
Lakshmi Rajdev United States	20	599 1.0×	300 0.6×	81 0.2×	223 0.5×	296 1.3×	64	1.1k
Pia Klausen Denmark	16	387 0.6×	118 0.3×	291 0.7×	246 0.6×	247 1.1×	33	928

Countries citing papers authored by E. Jaeger

Since Specialization

Citations

This map shows the geographic impact of E. Jaeger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Jaeger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Jaeger more than expected).

Fields of papers citing papers by E. Jaeger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Jaeger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Jaeger. The network helps show where E. Jaeger may publish in the future.

Co-authorship network of co-authors of E. Jaeger

This figure shows the co-authorship network connecting the top 25 collaborators of E. Jaeger. A scholar is included among the top collaborators of E. Jaeger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Jaeger. E. Jaeger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Atmaca, Akin, Alex Stein, Daniel Pink, et al.. (2025). 1857P Eftilagimod alpha (soluble LAG-3 protein) combined with first-line chemo-immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC): Updates from INSIGHT-003 (IKF614). Annals of Oncology. 36. S1000–S1000.

Al-Batran, S-E., Daniel Mueller, Akin Atmaca, et al.. (2023). A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology. ESMO Open. 8(5). 101623–101623. 5 indexed citations

Flatz, Lukas, M. Frueh, Stefan Diem, et al.. (2023). 1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC. Annals of Oncology. 34. S619–S619.

Jaeger, E., et al.. (2021). A biomechanical comparison of steel screws versus PLLA and magnesium screws for the Latarjet procedure. Archives of Orthopaedic and Trauma Surgery. 142(6). 1091–1098. 7 indexed citations

Al-Batran, S-E., Claudia Pauligk, Nils Homann, et al.. (2017). Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Annals of Oncology. 28. v616–v616. 16 indexed citations

Al‐Batran, Salah‐Eddin, Nils Homann, Harald Schmalenberg, et al.. (2017). Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.. Journal of Clinical Oncology. 35(15_suppl). 4004–4004. 164 indexed citations

Doeberitz, Magnus von Knebel, Matthias Kloor, Miriam Reuschenbach, et al.. (2016). Abstract A006: Frameshift peptide neoantigens as vaccine targets in microsatellite-unstable cancers. Cancer Immunology Research. 4(11_Supplement). A006–A006. 1 indexed citations

Kloor, Matthias, Miriam Reuschenbach, Julia Karbach, et al.. (2014). Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: A phase I/IIa clinical trial.. Journal of Clinical Oncology. 32(15_suppl). e14530–e14530. 10 indexed citations

Al-Batran, S., Ralf‐Dieter Hofheinz, Nils Homann, et al.. (2011). Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. Journal of Clinical Oncology. 29(15_suppl). 4070–4070. 4 indexed citations

10.

Al-Batran, S-E., Nils Homann, J. T. Hartmann, et al.. (2010). 5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. Journal of Clinical Oncology. 28(15_suppl). 4013–4013. 10 indexed citations

11.

Goekkurt, Eray, Salah‐Eddin Al‐Batran, Claudia Pauligk, et al.. (2008). Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Annals of Oncology. 20(3). 481–485. 7 indexed citations

12.

Walton, Senta M., Marco Gerlinger, Olga de la Rosa, et al.. (2006). Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. The Journal of Immunology. 177(11). 8212–8218. 21 indexed citations

13.

Zippelius, Alfred, Asma Gati, Senta M. Walton, et al.. (2006). Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunology Immunotherapy. 56(2). 249–258. 17 indexed citations

14.

Hecht, J. Randolph, Tanja Trarbach, E. Jaeger, et al.. (2005). A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Journal of Clinical Oncology. 23(16_suppl). LBA3–LBA3. 161 indexed citations

15.

Weidmann, Eckhart, Georg Heß, Stefan W. Krause, et al.. (2004). Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.. Blood. 104(11). 2640–2640. 14 indexed citations

16.

Knuth, Alexander, et al.. (1999). Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer. International Journal of Cancer. 81(1). 125–133. 35 indexed citations

17.

Neumann, Elena, Arne Engelsberg, Jean Decker, et al.. (1998). Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?. PubMed. 58(18). 4090–5. 133 indexed citations

18.

Jaeger, E., S Cayeux, Thomas Blankenstein, et al.. (1998). Strong Immunogenic Potential of a B7 Retroviral Expression Vector: Generation of HLA-B7-Restricted CTL Response Against Selectable Marker Genes. Human Gene Therapy. 9(1). 53–62. 21 indexed citations

19.

Jaeger, E., Helga Bernhard, Pedro Romero, et al.. (1996). Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens. International Journal of Cancer. 66(2). 162–169. 195 indexed citations

20.

Geboes, Karel, E. Jaeger, P. Rutgeerts, & G. Vantrappen. (1988). Symptomatic Gastrointestinal Metastases from Malignant Melanoma A Clinical Study. Journal of Clinical Gastroenterology. 10(1). 64–70. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact